(News Bulletin 247) – AstraZeneca announced Tuesday that it intends to present new data this week on the prevention of lower respiratory tract infections caused by RSV in infants, at a congress organized in Lisbon.
The pharmaceutical laboratory notably plans to lift the veil on the conclusions of a phase III trial aimed at determining the effectiveness of Beyfortus, the antibody it is developing with Sanofi, against infections caused by RSV in infants born in term or slightly premature (35 weeks gestation or more) at the start of the first RSV circulating season in their lives.
According to the group, these results reinforce the effectiveness of Beyfortus, with between 70% and 80% fewer infections than with a placebo.
RSV, better known as infant bronchiolitis, is a common and highly contagious seasonal virus that infects almost all children before the age of two.
These announcements come on the eve of the opening of the ‘ReSViNet’ conference dedicated to RSV infections, which will be held until Friday in Lisbon.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
-(plagies)_152444.jpg?fit=%2C&ssl=1)
